

ChinaAMC Hang Seng Hong Kong Biotech Index ETF

(Stock Code: 3069/9069)

Fund Factsheet



华夏基金(香港)有限公司
CHINA ASSET MANAGEMENT (HONG KONG) LIMITED

As of 30 Apr 2024

37/F, Bank of China Tower, 1 Garden Road, Hong Kong

Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the "Fund"), investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

- The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Hong Kong-Listed Biotech Index (the "Index").
- The Fund is passively managed. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
- The Fund's investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
- The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
- The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and mainland China). The Fund may be more volatile than a broadly-based fund.
- The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
- The Fund is subject to securities lending transactions risks, including the risk that the borrower may fail to return the securities in a timely manner.
- The Fund is subject to tracking error risk.
- If any suspension of the inter-counter transfer of Listed Units and/or any limitation on the level of services by brokers and CCASS participants occurs, unitholders will only be able to trade their units in the relevant counter.
- The market price of Listed Units traded in each counter may deviate significantly.
- Unitholders will receive distributions in the HKD only. Unitholder without HKD account may have to bear the fees and charges associated with currency conversion.
- The Fund has units traded in HKD, RMB and USD. Secondary market investors may be subject to additional costs or losses associated with foreign currency fluctuations between HKD and RMB/USD.
- Listed and Unlisted Classes are subject to different pricing and dealing arrangements. NAV per Unit of each class may be different due to different fees and cost. Dealing deadlines in respect of Listed and Unlisted Classes are different. Trading hours of SEHK applicable to Listed Class in the secondary market and dealing deadlines in respect of the Listed Class on the primary market or Unlisted Class are also different.
- Units of Listed Class are traded in the secondary market on an intraday basis at the prevailing market price, while Units of Unlisted Class are sold through intermediaries based on the dealing day-end NAV. Investors of Unlisted Class could redeem at NAV while investors of Listed Class in the secondary market could only sell at the prevailing market price and may have to exit the Fund at a significant discount. Investors of Unlisted Class may be at an advantage or disadvantage compared to investors of Listed Class.
- The trading price of Listed Units is driven by market factors such as the demand and supply of the units. Therefore, Listed Units may trade at a substantial premium or discount to the Fund's NAV.
- The Fund may at its discretion pay dividend out of capital or effectively out of capital. Payment of dividends out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the NAV per Unit of the Fund.


▲ Investment Objective

The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Hong Kong-Listed Biotech Index.

▲ Fund Information³

Manager	China Asset Management (Hong Kong) Limited
Trustee	HSBC Institutional Trust Services (Asia) Limited
Management Fee	0.5% p.a.
Base Currency	HKD
Index	Hang Seng Hong Kong-Listed Biotech Index
Exchange Listing	The Stock Exchange of Hong Kong Limited -Main Board
Fund Size	HKD 488.88 million
ETF Website	https://www.chinaamc.com.hk/product/chinaamc-hang-seng-hong-kong-biotech-index-etf-3069-hk-9069-hk/

▲ Fund Performance



Secondary Market Trading Information

	USD Counter	HKD Counter
Commencement of Dealing	30-Jun-2021	18-Mar-2021
Stock Code	9069	3069
Trading Currency	USD	HKD
Trading Board Lot Size	100 Units	100 Units
Bloomberg Fund Ticker	9069 HK	3069 HK
ISIN Code	HK0000744208	HK0000711199

Latest Fund Distribution⁵

Ex-Dividend Date	Distribution (HKD)
18-Dec-2023	0.03

▲ Cumulative Return^{1,2}

	1 Month	6 Month	1 Year	3 Year	5 Year	Since Inception ⁴
ChinaAMC Hang Seng Hong Kong Biotech Index ETF ¹	+0.72%	-25.43%	-35.34%	-68.64%	-	-66.04%
Hang Seng Hong Kong-Listed Biotech Index (Net Total Return) ²	+0.76%	-25.32%	-35.09%	-68.16%	-	-65.61%

▲ Yearly Return^{1,2}

	2019	2020	2021 ⁴	2022	2023	2024YTD
ChinaAMC Hang Seng Hong Kong Biotech Index ETF ¹	-	-	-30.99%	-18.31%	-23.59%	-21.16%
Hang Seng Hong Kong-Listed Biotech Index (Net Total Return) ²	-	-	-31.08%	-17.72%	-23.15%	-21.09%

¹ Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is calculated on NAV-to-NAV, with dividend reinvested. With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply. Performance analytics here refer to HKD counter unit. With effect from 5 June 2023, the portfolio of the Fund was rebalanced to reflect the changes to the Index methodology. The performance of the Fund prior to 5 June 2023 was achieved under circumstances that no longer apply.

² Based on net total return, denominated in HKD

³ Please refer to the Fund's prospectus for further details (including fees).

⁴ Calculated since 17 March 2021, the first official NAV date of the fund.

⁵ The Manager intends to distribute income to Unitholders at least annually (usually in December), subject to the Manager's discretion, having regard to the Fund's net income after fees and costs. All Units (whether USD, RMB or HKD traded Units) will receive distributions in HKD only. Distributions may be paid out of capital or effectively out of capital as well as income at the Manager's discretion.

Source: China Asset Management (Hong Kong) Limited and Bloomberg unless specified otherwise.


ChinaAMC Hang Seng Hong Kong Biotech Index ETF

(Stock Code: 3069/9069)

Fund Factsheet



▲ Portfolio Allocation



▲ Participating Dealers

ABN AMRO Clearing Hong Kong Limited
Barclays Bank PLC
BNP Paribas
China International Capital Corporation (Hong Kong) Limited
China Merchants Securities (HK) Co Ltd
Citigroup Global Markets Asia Limited
Credit Suisse Securities (Hong Kong) Limited
DBS Vickers (Hong Kong) Limited
Goldman Sachs (Asia) Securities Limited
Guotai Junan Securities (Hong Kong) Limited
Haitong International Securities Group Limited
Huatai Financial Holdings (Hong Kong) Limited
J.P. Morgan Broking (Hong Kong) Limited
Korea Investment & Securities Asia Limited
Merrill Lynch Far East Limited
Mirae Asset Securities (HK) Limited
The Hongkong and Shanghai Banking Corporation Limited
Yue Xiu Securities Company Limited
Zhongtai International Securities Limited

▲ Top 10 Holdings

Security Name	Weight
BEIGENE LT	10.30%
CSPC PHARM GRP	10.02%
INNOVENT BIOLO	9.11%
WUXI BIOLOGICS	7.84%
SINO BIOPHARMAC	5.27%
AKESO INC	5.26%
GIANT BIOGENE	3.72%
HANSOH PHARMAC	3.58%
HUTCHMED CHINA	2.97%
GENSCRIPT BIOTE	2.78%

▲ Market Makers

HKD Counter
Flow Traders Hong Kong Limited
Vivienne Court Trading Pty. Ltd.
Optiver Trading Hong Kong Limited

USD Counter
Flow Traders Hong Kong Limited
Vivienne Court Trading Pty. Ltd.
Optiver Trading Hong Kong Limited
Please refer to the Hong Kong Exchanges and Clearing Limited's website at www.hkex.com.hk for the latest lists of Market Makers.

About China Asset Management (Hong Kong) Limited

Founded in 2008, China Asset Management (Hong Kong) Limited ("ChinaAMC (HK)") is a wholly-owned subsidiary of China Asset Management Company Limited and stands as one of the top Chinese fund management firms in Hong Kong. As a China-focused market leader, the company has amassed an impressive performance history in both active and passive investments over the past 15 years. Boasting robust expertise in a variety of asset classes, such as Greater China equities, Asian and global fixed income, and money markets, ChinaAMC (HK) adopts a global outlook to build a versatile platform catering to institutional and retail investors in the region and worldwide, all while envisioning "Beyond China Expert".

Customer Hotline: (852) 3406 8686

Website: www.chinaamc.com.hk

Email: hkfund_services@chinaamc.com

Risk Warning

Investment involves risks. The price of the Fund's units may go up as well as down. Past performance is not indicative of future performance, future return is not guaranteed and a loss of your original capital may occur. This material does not constitute an offer or solicitation of any transaction in any securities or collective investment schemes, nor does it constitute any investment advice. This document is provided for information purposes only and shall not be relied upon for making any investment decision. Certain information or data in this document has been obtained from unaffiliated third parties; we have reasonable belief that such information or data is accurate, complete and up to the date as indicated; China Asset Management (Hong Kong) Limited accepts responsibility for accurately reproducing such data and information but makes no warranty or representation as to the completeness or accuracy of data and information sourced from such unaffiliated third parties. You should read the Fund's offering documents for further details, including risk factors. If necessary, you should seek independent professional advice. This material has been prepared and issued by China Asset Management (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission.

The mark and name Hang Seng Hong Kong-Listed Biotech Index is proprietary to Hang Seng Data Services Limited ("HSDS") which has licensed its compilation and publication to Hang Seng Indexes Company Limited ("HSIL"). HSIL and HSDS have agreed to the use of, and reference to, the Hang Seng Hong Kong-Listed Biotech Index by China Asset Management (Hong Kong) Limited ("the Issuer") in connection with the ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the "Product"). However, neither HSIL nor HSDS warrants, represents or guarantees to any person the accuracy or completeness of the Hang Seng Hong Kong-Listed Biotech Index, its computation or any information related thereto and no warranty, representation or guarantee of any kind whatsoever relating to the Hang Seng Hong Kong-Listed Biotech Index is given or may be implied. Neither HSIL nor HSDS accepts any responsibility or liability for any economic or other loss which may be directly or indirectly sustained by any person as a result of or in connection with the use of and/or reference to the Hang Seng Hong Kong-Listed Biotech Index by the Issuer in connection with the Product, or any inaccuracies, omissions or errors of HSIL in computing the Hang Seng Hong Kong-Listed Biotech Index. Any person dealing with the Product shall place no reliance whatsoever on HSIL and/or HSDS nor bring any claims or legal proceedings against HSIL and/or HSDS in any manner whatsoever. For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker or other person dealing with the Product and HSIL and/or HSDS and must not be construed to have created such relationship.